HLA Specific human cytomegalovirus Multi-epitope adenovirus DNA Vaccine of Chinese population

Abstract

The present invention discloses an HLA Specific human cytomegalovirus Multi-epitope adenovirus DNA Vaccine of Chinese population, which consists of human cytomegalovirus tandem sequence CTL*Th and adenovirus expression vector pAd5F35, wherein the human cytomegalovirus tandem sequence CTL*Th comprises a nucleotide sequence represented by SEQ ID No.1. The nucleotide sequence comprises the nucleotide sequences of 83 antigen epitopes of 15 encoding proteins of human cytomegalovirus. Furthermore, the sequence covers 14 HLA I allelomorphic gene sites and 7 HLA II allelomorphic gene sites. The coverage percent of the HCMV tandem epitope DNA vaccine representing excellent HLA is 92.07 percent in average, and is used for preventing the forming of HCMV disease in the steps of adhering, duplicating and re-activating of the virus. The in vetro experiment shows that the vaccine of the invention has excellent immune effect and overcomes the defects of inferior immunogenicity and limited immune range of the prior HCMV vaccine.

Description

technical field [0001] The invention relates to a nucleic acid vaccine and its construction and application, in particular to a human cytomegalovirus (HCMV) nucleic acid vaccine, that is, a Chinese population HLA-specific human cytomegalovirus multi-epitope adenovirus nucleic acid vaccine and its construction and application. Background technique [0002] HCMV disease has become a common and important complication of organ transplantation and intrauterine infection, and is an important cause of transplantation failure, fetal death and malformation. Existing HCMV vaccines have shortcomings such as weak immunogenicity, limited immune range, and small immune response, and cannot effectively prevent and treat HCMV infection, mainly because: (1) the part that can really cause immune response in the antigen molecule is the one that is compatible with the host The antigenic epitope specifically bound by the human leukocyte antigen (HLA) molecule is the most basic structural and fun...

AI Technical Summary

Problems solved by technology

Overseas research on HCMV epitope vaccines targets European and African populations, whose HLA genetic background is different from that of the Chinese population. The epitope vaccines developed by them are difficult to be presented by HLA molecules in the Chinese population, and cannot elicit an effective protective immune response

At present, there is no report on HCMV multi-epitope vaccine in China, and the spatial distribution of Chinese population and ethnicity is extremely uneven, and the spatial distribution of HLA gene frequency and haplotype frequency in the population is highly heterogeneous, so the development of HLA distribution for the Chinese population The HCMV tandem epitope vaccine with strong immune effect is the key to the prevention and control of HCMV in my country

Images